Stock Track | SH PHARMA Plummets 5.11% as Q3 Net Profit Drops 38% on Higher Impairment Provisions

Stock Track10-31

Shares of SH PHARMA (02607) experienced a significant decline during intraday trading on Friday, plummeting 5.11% to HK$11.71. The sharp drop came in the wake of the company's release of its third-quarter financial results for 2025, which revealed mixed performance across different timeframes.

According to the financial report, SH PHARMA demonstrated overall growth for the first nine months of 2025. The company's revenue reached RMB 215.07 billion, marking a 2.60% increase year-on-year, while net profit attributable to shareholders rose impressively by 26.96% to RMB 5.147 billion. However, the market's negative reaction appears to be focused on the company's third-quarter performance specifically.

In the third quarter alone, SH PHARMA reported a 4.65% increase in revenue to RMB 73.479 billion. Despite this top-line growth, the company's bottom line took a significant hit, with net profit attributable to shareholders declining by 38.13% to RMB 688 million. The primary factor behind this profit slump was attributed to higher asset impairment provisions during the quarter, raising concerns among investors about the company's asset quality and future financial stability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198805074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198805074","market":"us","top_or_hot":-1,"title":"Stock Track | SH PHARMA Plummets 5.11% as Q3 Net Profit Drops 38% on Higher Impairment Provisions","media":"Stock Track","content":"<p>Shares of SH PHARMA (02607) experienced a significant decline during intraday trading on Friday, plummeting 5.11% to HK$11.71. The sharp drop came in the wake of the company's release of its third-quarter financial results for 2025, which revealed mixed performance across different timeframes.</p>\n\n<p>According to the financial report, SH PHARMA demonstrated overall growth for the first nine months of 2025. The company's revenue reached RMB 215.07 billion, marking a 2.60% increase year-on-year, while net profit attributable to shareholders rose impressively by 26.96% to RMB 5.147 billion. However, the market's negative reaction appears to be focused on the company's third-quarter performance specifically.</p>\n\n<p>In the third quarter alone, SH PHARMA reported a 4.65% increase in revenue to RMB 73.479 billion. Despite this top-line growth, the company's bottom line took a significant hit, with net profit attributable to shareholders declining by 38.13% to RMB 688 million. The primary factor behind this profit slump was attributed to higher asset impairment provisions during the quarter, raising concerns among investors about the company's asset quality and future financial stability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SH PHARMA Plummets 5.11% as Q3 Net Profit Drops 38% on Higher Impairment Provisions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SH PHARMA Plummets 5.11% as Q3 Net Profit Drops 38% on Higher Impairment Provisions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 11:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of SH PHARMA (02607) experienced a significant decline during intraday trading on Friday, plummeting 5.11% to HK$11.71. The sharp drop came in the wake of the company's release of its third-quarter financial results for 2025, which revealed mixed performance across different timeframes.</p>\n\n<p>According to the financial report, SH PHARMA demonstrated overall growth for the first nine months of 2025. The company's revenue reached RMB 215.07 billion, marking a 2.60% increase year-on-year, while net profit attributable to shareholders rose impressively by 26.96% to RMB 5.147 billion. However, the market's negative reaction appears to be focused on the company's third-quarter performance specifically.</p>\n\n<p>In the third quarter alone, SH PHARMA reported a 4.65% increase in revenue to RMB 73.479 billion. Despite this top-line growth, the company's bottom line took a significant hit, with net profit attributable to shareholders declining by 38.13% to RMB 688 million. The primary factor behind this profit slump was attributed to higher asset impairment provisions during the quarter, raising concerns among investors about the company's asset quality and future financial stability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1198805074","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198805074","pubTimestamp":1761881681,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of SH PHARMA (02607) experienced a significant decline during intraday trading on Friday, plummeting 5.11% to HK$11.71. The sharp drop came in the wake of the company's release of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02607":"上海医药"},"translate_title":"个股轨迹|SH医药暴跌5.11%Q3净利降38%减值拨备增加","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02607":1},"content_text":"Shares of SH PHARMA (02607) experienced a significant decline during intraday trading on Friday, plummeting 5.11% to HK$11.71. The sharp drop came in the wake of the company's release of its third-quarter financial results for 2025, which revealed mixed performance across different timeframes.\nAccording to the financial report, SH PHARMA demonstrated overall growth for the first nine months of 2025. The company's revenue reached RMB 215.07 billion, marking a 2.60% increase year-on-year, while net profit attributable to shareholders rose impressively by 26.96% to RMB 5.147 billion. However, the market's negative reaction appears to be focused on the company's third-quarter performance specifically.\nIn the third quarter alone, SH PHARMA reported a 4.65% increase in revenue to RMB 73.479 billion. Despite this top-line growth, the company's bottom line took a significant hit, with net profit attributable to shareholders declining by 38.13% to RMB 688 million. The primary factor behind this profit slump was attributed to higher asset impairment provisions during the quarter, raising concerns among investors about the company's asset quality and future financial stability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198805074","isCrawlerRequest":true}